Carcinoma of the apocrine glands of the anal sac in dogs: 113 cases (1985–1995)
…, RM Gamblin, DH Thamm, SE Lana… - Journal of the …, 2003 - Am Vet Med Assoc
Objective —To characterize the signalment, clinical signs, biological behavior, and
response to treatment of carcinoma of the apocrine glands of the anal sac in dogs. Design —…
response to treatment of carcinoma of the apocrine glands of the anal sac in dogs. Design —…
Evaluation of prognostic factors associated with outcome in dogs with multiple cutaneous mast cell tumors treated with surgery with and without adjuvant treatment: 54 …
…, EJ Ehrhart, DH Thamm, SE Lana - Journal of the …, 2006 - Am Vet Med Assoc
Objective —To evaluate prognostic factors associated with outcome of dogs with multiple
cutaneous mast cell tumors (MCTs) treated with surgery with or without adjuvant treatment. …
cutaneous mast cell tumors (MCTs) treated with surgery with or without adjuvant treatment. …
Incidence and prognostic importance of lymph node metastases in dogs with appendicular osteosarcoma: 228 cases (1986–2003)
…, MH Lafferty, SJ Withrow, SE Lana - Journal of the …, 2005 - Am Vet Med Assoc
Objective —To determine the incidence of regional lymph node metastasis in dogs with
appendicular osteosarcoma and determine whether regional lymph node metastasis was …
appendicular osteosarcoma and determine whether regional lymph node metastasis was …
CCNU in the treatment of canine epitheliotropic lymphoma
…, KM Rassnick, HT Power, SE Lana… - Journal of veterinary …, 2006 - Wiley Online Library
This retrospective study examined the use of CCNU (1‐[2‐chloroethyl]3‐cyclohexyl‐1‐nitrosurea)
in 36 dogs with epitheliotropic lymphoma. Thirty‐one (86%) dogs had the cutaneous …
in 36 dogs with epitheliotropic lymphoma. Thirty‐one (86%) dogs had the cutaneous …
Evaluation of 12-and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors
…, SW Atwater, JK Carreras, SE Lana… - American journal of …, 2010 - Am Vet Med Assoc
Objective —To evaluate the effectiveness of masitinib for the treatment of nonresectable
mast cell tumors (MCTs) in dogs at 12 and 24 months after onset of treatment. Animals —132 …
mast cell tumors (MCTs) in dogs at 12 and 24 months after onset of treatment. Animals —132 …
Cyclooxygenase‐2 expression in canine appendicular osteosarcomas
MN Mullins, SE Lana, WS Dernell… - Journal of Veterinary …, 2004 - Wiley Online Library
Osteosarcoma is the most common primary bone tumor in dogs and it has a high mortality
rate from distant metastatic disease. Targeted adjuvant therapies are needed to prolong …
rate from distant metastatic disease. Targeted adjuvant therapies are needed to prolong …
Utility of polymerase chain reaction for analysis of antigen receptor rearrangement in staging and predicting prognosis in dogs with lymphoma
SE Lana, TL Jackson, RC Burnett… - Journal of veterinary …, 2006 - Wiley Online Library
In lymphoid neoplasia, molecular assays to confirm clonality rely on the fact that lymphoid
cells normally contain DNA regions with unique sequences, resulting from recombination of …
cells normally contain DNA regions with unique sequences, resulting from recombination of …
Single agent chemotherapy with doxorubicin for feline lymphoma: a retrospective study of 19 cases (1994–1997)
O Kristal, SE Lana, GK Ogilvie… - Journal of Veterinary …, 2001 - Wiley Online Library
Medical records of 21 cats with confirmed lymphoma treated with single‐agent doxorubicin
were reviewed. Nineteen cats met the inclusion criteria for this retrospective study. …
were reviewed. Nineteen cats met the inclusion criteria for this retrospective study. …
The use of complementary and alternative therapies in dogs and cats with cancer
SE Lana, LR Kogan, KA Crump… - Journal of the …, 2006 - meridian.allenpress.com
The use of complementary and alternative medical therapies is becoming widespread. The
objective of this study was to examine the use of complementary and alternative therapies in …
objective of this study was to examine the use of complementary and alternative therapies in …
Adjuvant sirolimus does not improve outcome in pet dogs receiving standard-of-care therapy for appendicular osteosarcoma: a prospective, randomized trial of 324 …
…, EP Berger, WC Kisseberth, ME Brown, SE Lana… - Clinical Cancer …, 2021 - AACR
Purpose: The mTOR pathway has been identified as a key nutrient signaling hub that participates
in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is …
in metastatic progression of high-grade osteosarcoma. Inhibition of mTOR signaling is …